Gadolinium-based mostly contrast agents (GBCAs) are extensively used in magnetic resonance imaging (MRI) to improve the visibility of blood vessels, tumors, inflammation, as well as other internal constructions. When generally regarded as Protected, worries about GBCA toxicity have emerged over the past two decades—specially in people with impair